CD3-positive plasmablastic lymphoma reported in two cases: A potential diagnostic caveat.

Indian J Pathol Microbiol

Department of Pathology, Faculty of Medicine, Universiti Kebangsaan, Malaysia Medical Centre, Kuala Lumpur, Malaysia.

Published: November 2021

Plasmablastic lymphoma (PBL) is a rare aggressive subtype of mature large B cell lymphoma involving almost exclusively the extranodal regions particularly the oral cavity, frequently described in immunocompromised patients. PBL is characterized histologically by diffuse proliferation of large neoplastic cells resembling B immunoblasts or plasmablasts. The diagnosis of PBL can be difficult due to its ambiguous histopathological features mimicking most large cell lymphomas and lacking a distinctive immunophenotypic pattern. They typically lack expression of CD20 and CD79a but may express plasma cell marker, CD138. Aberrant immunoexpression of CD3, a T-cell marker in PBL in the absence of other B-cell markers is exceptionally rare, may potentially lead to incorrect interpretation. Herein, we report a case series of CD3-positive PBL of oral cavity in two individuals, which were initially misdiagnosed as high-grade T-cell lymphomas including extranodal NK/T-cell lymphoma, nasal type. Useful distinguishing clinical settings, histomorphological features, immunohistochemistry and molecular expression profiles of PBL are discussed.

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_616_20DOI Listing

Publication Analysis

Top Keywords

plasmablastic lymphoma
8
large cell
8
oral cavity
8
pbl
6
cd3-positive plasmablastic
4
lymphoma
4
lymphoma reported
4
reported cases
4
cases potential
4
potential diagnostic
4

Similar Publications

Plasmablastic lymphoma (PbL) is a subtype of diffuse large B-cell lymphoma, primarily linked to human immunodeficiency virus (HIV) infection. This case report presents a 34-year-old HIV-positive patient who exhibited unusual signs of pleural thickening and effusion. Initial evaluations, including imaging and pleural fluid analysis, suggested thoracic empyema.

View Article and Find Full Text PDF

Plasmablastic lymphoma (PBL) is a malignant lymphoma with poor prognosis that occurs in immunocompromised and elderly patients. We describe the case of a 75-year-old woman with PBL as a methotrexate-associated lymphoproliferative disorder (MTX-LPD). She presented with multiple oral ulcers and mass-like shadows in the lung fields.

View Article and Find Full Text PDF
Article Synopsis
  • * It typically occurs in males and is characterized by extra-nodal masses, often found in the oral cavity or gastrointestinal tract, but a unique case involved a 93-year-old female without HIV showing pericardial effusion instead.
  • * Diagnosis of PBL can be challenging due to atypical presentations; thus, awareness, thorough immunohistochemistry, and clinical correlation are critical for accurate identification.
View Article and Find Full Text PDF

BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review.

Crit Rev Oncol Hematol

January 2025

Department of Myeloma and Lymphoma, Beijing GoBroad Boren Hospital, Beijing 100070, China; Beijing Branch Center of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100070, China; Myeloma Research Institute, Beijing GoBroad Boren Hospital, Beijing 100070, China. Electronic address:

Article Synopsis
  • Richter transformation poses a continued risk for chronic lymphocytic leukemia (CLL) patients, even with advancements in targeted therapies like Bruton's tyrosine kinase inhibitor, particularly in a reported case of a 61-year-old male who experienced this change post-treatment.
  • After stopping ibrutinib during the COVID-19 pandemic, the patient developed a related plasmablastic lymphoma (PBL), diagnosed through histological analysis of a tumor in the supraclavicular area and bone marrow infiltration.
  • The patient underwent treatment with a combination of CHP, venetoclax, and brentuximab vedotin, followed by successful BCMA CAR-T cell therapy, resulting in complete remission and highlighting the potential
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!